PURPOSE: To understand the effect of patient preferences on thyroid cancer surveillance intensity. PATIENTS AND METHODS: Eligible patients diagnosed with thyroid cancer between January 1, 2014, and December 31, 2015, from the Georgia and Los Angeles County SEER registries were surveyed between February 2017 and October 2018 (N = 2,632; response rate, 63%). Patient reports on health care utilization in the past year and responses to the validated Medical Maximizer-Minimizer Scale were linked to SEER data in the 2,183 disease-free patients. Ordered logistic regression was performed using a cumulative logit with nonproportional odds. RESULTS: Of disease-free patients, 31.6% were classified as minimizers, 42.5% as moderate maximizers, and 25.9% as strong maximizers. In the past year, 25.2%, 27.3%, and 38.5% of minimizers, moderate maximizers, and strong maximizers, respectively, had ≥ 4 doctor visits, and 18.3%, 24.9%, and 29.5%, respectively, had ≥ 2 neck ultrasounds. When controlling for age, sex, race and ethnicity, comorbidity, stage, and SEER site, strong maximizers (compared with minimizers) were significantly more likely to report ≥ 4 doctor visits (odds ratio [OR], 1.45; 95% CI, 1.10-1.92), ≥ 2 neck ultrasounds (OR, 1.58; 95% CI, 1.17-2.14), ≥ 1 radioactive iodine scan (OR, 1.73; 95% CI, 1.19-2.50), and ≥ 1 additional imaging study (OR, 2.06; 95% CI, 1.56-2.72). CONCLUSION: Among patients with thyroid cancer who have been declared disease free, preference for a more maximal versus minimal approach to medical care is associated with increased number of physician visits and imaging tests. Because increased surveillance does not clearly correlate with improved outcomes, poses potential risks to patients, and contributes to increased healthcare costs, stronger consideration of the role of patient preferences is necessary when framing discussions on surveillance.
PURPOSE: To understand the effect of patient preferences on thyroid cancer surveillance intensity. PATIENTS AND METHODS: Eligible patients diagnosed with thyroid cancer between January 1, 2014, and December 31, 2015, from the Georgia and Los Angeles County SEER registries were surveyed between February 2017 and October 2018 (N = 2,632; response rate, 63%). Patient reports on health care utilization in the past year and responses to the validated Medical Maximizer-Minimizer Scale were linked to SEER data in the 2,183 disease-free patients. Ordered logistic regression was performed using a cumulative logit with nonproportional odds. RESULTS: Of disease-free patients, 31.6% were classified as minimizers, 42.5% as moderate maximizers, and 25.9% as strong maximizers. In the past year, 25.2%, 27.3%, and 38.5% of minimizers, moderate maximizers, and strong maximizers, respectively, had ≥ 4 doctor visits, and 18.3%, 24.9%, and 29.5%, respectively, had ≥ 2 neck ultrasounds. When controlling for age, sex, race and ethnicity, comorbidity, stage, and SEER site, strong maximizers (compared with minimizers) were significantly more likely to report ≥ 4 doctor visits (odds ratio [OR], 1.45; 95% CI, 1.10-1.92), ≥ 2 neck ultrasounds (OR, 1.58; 95% CI, 1.17-2.14), ≥ 1 radioactive iodine scan (OR, 1.73; 95% CI, 1.19-2.50), and ≥ 1 additional imaging study (OR, 2.06; 95% CI, 1.56-2.72). CONCLUSION: Among patients with thyroid cancer who have been declared disease free, preference for a more maximal versus minimal approach to medical care is associated with increased number of physician visits and imaging tests. Because increased surveillance does not clearly correlate with improved outcomes, poses potential risks to patients, and contributes to increased healthcare costs, stronger consideration of the role of patient preferences is necessary when framing discussions on surveillance.
Authors: Angela B Mariotto; K Robin Yabroff; Yongwu Shao; Eric J Feuer; Martin L Brown Journal: J Natl Cancer Inst Date: 2011-01-12 Impact factor: 13.506
Authors: Megan R Haymart; Mousumi Banerjee; Andrew K Stewart; Ronald J Koenig; John D Birkmeyer; Jennifer J Griggs Journal: JAMA Date: 2011-08-17 Impact factor: 56.272
Authors: Laura Y Wang; Benjamin R Roman; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly Journal: Surgery Date: 2015-12-31 Impact factor: 3.982
Authors: Laura D Scherer; Tanner J Caverly; James Burke; Brian J Zikmund-Fisher; Jeffrey T Kullgren; Douglas Steinley; Denis M McCarthy; Meghan Roney; Angela Fagerlin Journal: Health Psychol Date: 2016-09-12 Impact factor: 4.267
Authors: Anna M Sawka; David P Goldstein; Lehana Thabane; James D Brierley; Richard W Tsang; Lorne Rotstein; Shamila Kamalanathan; Boyu Zhao; Amiram Gafni; Sharon Straus; Shereen Ezzat Journal: Endocr Pract Date: 2008-03 Impact factor: 3.443
Authors: Lesly A Dossett; Nicole M Mott; Brooke C Bredbeck; Ton Wang; Chad Tc Jobin; Tasha M Hughes; Sarah T Hawley; Brian J Zikmund-Fisher Journal: J Surg Res Date: 2021-11-19 Impact factor: 2.192
Authors: Nina Jackson Levin; Anao Zhang; David Reyes-Gastelum; Debbie W Chen; Ann S Hamilton; Bradley Zebrack; Megan R Haymart Journal: J Cancer Surviv Date: 2021-10-11 Impact factor: 4.062
Authors: Kevin J Kovatch; David Reyes-Gastelum; Jennifer A Sipos; Elaine M Caoili; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-12-23 Impact factor: 6.223
Authors: Nicole Mott; Ton Wang; Jacquelyn Miller; Nicholas L Berlin; Sarah Hawley; Reshma Jagsi; Brian J Zikmund-Fisher; Lesly A Dossett Journal: Ann Surg Oncol Date: 2020-07-27 Impact factor: 5.344
Authors: Maria Papaleontiou; Debbie W Chen; Mousumi Banerjee; David Reyes-Gastelum; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: Thyroid Date: 2021-04-23 Impact factor: 6.506
Authors: Maria Papaleontiou; Bradley Zebrack; David Reyes-Gastelum; Andrew J Rosko; Sarah T Hawley; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: J Cancer Surviv Date: 2020-09-16 Impact factor: 4.062
Authors: Dana M Hartl; Joanne Guerlain; Ingrid Breuskin; Julien Hadoux; Eric Baudin; Abir Al Ghuzlan; Marie Terroir-Cassou-Mounat; Livia Lamartina; Sophie Leboulleux Journal: Cancers (Basel) Date: 2020-11-06 Impact factor: 6.639